A minimum agreed set of outcomes could let pharmacists compare chronic kidney disease (CKD) interventions head-to-head and cut the heterogeneity that has long muddied trials.
Ashkon Ardavani, PharmD, PhD
Advertisement
Articles by Ashkon Ardavani, PharmD, PhD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Pharmacy Times
1
New Lipid Drugs and What Pharmacists Need to Know
2
Pennsylvania Confirms First Measles Deaths in 35 Years as US Case Count Tops 2900
3
Fast-Acting Meloxicam Demonstrates Postoperative Pain Relief and Opioid-Sparing Potential
4
Diabetes Cohort Study Reveals Prolonged Delays in Pneumococcal Vaccination
5